Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study
Ruxolitinib cream provided superior improvements versus vehicle in AD signs and symptoms in children with mild-to-moderate AD and was well tolerated.
Authors
- Xuejun Chen (ORCID: https://orcid.org/0000-0001-9192-0440)
- Amy S. Paller (ORCID: https://orcid.org/0000-0001-6187-6549)
- April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
- Andrea L. Zaenglein (ORCID: https://orcid.org/0000-0002-2507-7130)
- Dareen Siri
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- Lara Wine Lee (ORCID: https://orcid.org/0000-0001-6739-4508)
- Lawrence F. Eichenfield (ORCID: https://orcid.org/0000-0002-2760-0474)
- Alim R Devani
- Seth Forman (ORCID: https://orcid.org/0000-0001-5800-1856)
- Howard Kallender (ORCID: https://orcid.org/0000-0001-5634-883X)
- Weily Soong (ORCID: https://orcid.org/0000-0002-2701-7035)
- Brett Angel
- Qian Li (ORCID: https://orcid.org/0000-0003-1300-3377)
- Eric L. Simpson (ORCID: https://orcid.org/0000-0002-8793-7087)
- Megha M. Tollefson
Institutions
- Northwestern University (US)
- Mayo Clinic (US)
- Medical University of South Carolina (US)
- Henry Ford Health System (US)
- University of California, Los Angeles (US)
- Oregon Health & Science University (US)
- University of California San Diego (US)
- Heritage Medical Research Clinic (CA)
- Mayo Clinic in Arizona (US)
- Community Cancer Center (US)
- Penn State Milton S. Hershey Medical Center (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1016/j.jaad.2025.05.1385
- Citations
- 5
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 10.02